Is ARVINAS, INC. (ARVN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.0% / 30% | 78.5% / 30% | 0.7% / 30% | 14.62% / 5% | ✗ NOT HALAL |
| DJIM | 1.0% / 33% | 78.5% / 33% | 0.7% / 33% | 14.62% / 5% | ✗ NOT HALAL |
| MSCI | 1.2% / 33% | 95.5% / 33% | 0.9% / 33% | 14.62% / 5% | ✗ NOT HALAL |
| S&P | 1.0% / 33% | 78.5% / 33% | 0.7% / 33% | 14.62% / 5% | ✗ NOT HALAL |
| FTSE | 1.2% / 33% | 95.5% / 33% | 0.9% / 50% | 14.62% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -754.7% | |
| Net Margin | -30.8% | |
| Return on Equity (ROE) | -16.2% | |
| Return on Assets (ROA) | -7.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$274M |
| Free Cash Flow | -$276M |
| Total Debt | $9M |
| Debt-to-Equity | 2.1 |
| Current Ratio | 4.9 |
| Total Assets | $718M |
Price & Trading
| Last Close | $10.87 |
| 50-Day MA | $12.54 |
| 200-Day MA | $10.08 |
| Avg Volume | 819K |
| Beta | 1.9 |
|
52-Week Range
$5.90
| |
About ARVINAS, INC. (ARVN)
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ARVINAS, INC. (ARVN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ARVINAS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ARVINAS, INC.'s debt ratio?
ARVINAS, INC.'s debt ratio is 1.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.2%.
What are ARVINAS, INC.'s key financial metrics?
ARVINAS, INC. has a market capitalization of $649M, and revenue of $263M. The company maintains a gross margin of 100.0% and a net margin of -30.8%. Return on equity stands at -16.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.